Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin plus proton pump inhibitor for functional dyspepsia with duodenal eosinophilia
ChiCTR2300069313Phase 4Recruiting
- Sponsor
- Peking University Third Hospital Gastroenterology Department
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifaximin in functional dyspepsia (FD) (4 arms), sponsored by Peking University Third Hospital Gastroenterology Department. Primary endpoint: Symptom relief rate at week 8. Started Mar 2023; status: recruiting.
02
Drugs
rifaximin
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on ChiCTR2300069313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069313.